Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Targovax. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Targovax's earnings available for a low price, and how does
this compare to other companies in the same industry?
Targovax is not considered high growth as it is expected to be loss making for the next 1-3 years.
Targovax's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Targovax's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Oystein Soug, M.Sc has been the Chief Executive Officer of Targovax ASA since November 1, 2016. Mr. Soug has 17 years' experience in international finance and corporate development and has been based primarily in Russia and Norway. He served as Chief Financial Officer of Targovax ASA from June 1, 2015 until October 2016. He served as the Chief Financial Officer of Algeta ASA(Orkla Group) since June 1, 2008 and builds up the functions of Finance, IR, Compliance, IT and HR. Mr. Soug served as the Chief Financial Officer of SladCo (Orkla Foods CIS) and Project Manager in Orkla's Corporate Development M&A team at Norwegian Orkla group. He joined the Orkla Group in 2002. Prior to Orkla Group, Mr. Soug co-founded and managed Webmercs and he spent nearly six years in banking with European Bank for Reconstruction and Development (in Russia), Credit Suisse (China) and Dresdner Bank (Germany). He served as Vice Chairman and Director of Bionor Pharma ASA since May 15, 2013 until March 19, 2016. Mr. Soug has an MSc in Economics and Finance, a Master of International Management (CEMS) and a BA in Business, all from the University of St Gallen in Switzerland.
Øystein's compensation has increased whilst company is loss making.
Øystein's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Targovax management team is about average.
Chief Executive Officer
VP & Head of CMC
Chief Medical Officer
Chief Business Officer
Vice President of Clinical Development
Vice President of Quality Assurance
Vice President of Business Development
Chief Financial Officer
Chief Scientific Adviser
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Targovax board of directors is about average.
Targovax ASA, a clinical stage immuno-oncology company, engages in the development of targeted immunotherapies for cancer patients. It is developing a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers; and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. The company’s product candidates include TG01, which is in Phase I/II clinical trial for the treatment of patients with resected adenocarcinoma of the pancreas; TG02 that is in Phase Ib exploratory trial for the treatment of colorectal cancer; and ONCOS-102 that is in Phase I/II study for the treatment of mesothelioma, ovarian cancer, colorectal cancer, and advanced prostate cancer. The company has clinical collaboration agreements with the Parker Institute for Cancer Immunotherapy and Cancer Research Institute. Targovax ASA is based in Oslo, Norway.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.